|
|
 |
|
Viewing report
|
|
|
|
Novartis AG: PharmaVitae Report
Datamonitor, Nov 2011, Pages: 103
This analysis examines the historical and forecast performance for Novartis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Novartis's strategic outlook across the next 6 years.
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
Strategic insight into the prospects for Novartis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Novartis's performance against key rivals in the prescription pharmaceutical sector
- Assess Novartis's industry-leading diversification strategy, bolstered most recently via acquisition of the ophthalmology specialist Alcon
- Analyze the internal growth drivers which are expected to position Novartis as the industry's leading prescription pharmaceutical player by 2016
|
|
|
|
